# A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction

Study · id `cardio:ct-nct07938411` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07938411](<https://clinicaltrials.gov/study/NCT07938411>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07938411

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 10000 participants.

## Technical summary

Registry record NCT07938411. Randomized; double masking; primary purpose treatment. Start 2026-11-30 (anticipated); primary completion 2030-10-22 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 10000 participants (planned count; ClinicalTrials.gov record NCT07938411, source copy `cardio:ctgov-nct07938411-2026-11-16`, retrieved 2026-11-18)
- Planned start: 2026-11-30 (anticipated) (ClinicalTrials.gov record NCT07938411, source copy `cardio:ctgov-nct07938411-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2030-10-22 (anticipated) (ClinicalTrials.gov record NCT07938411, source copy `cardio:ctgov-nct07938411-2026-11-16`, retrieved 2026-11-18)
- Completion: 2030-10-22 (anticipated) (ClinicalTrials.gov record NCT07938411, source copy `cardio:ctgov-nct07938411-2026-11-16`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07938411-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction
- Acronym: PINNACLE-MI
- Condition: Myocardial Infarction
- Intervention (Drug): Pacibekitug
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: e36962d797a694a6d48c82d3391243169fa999f549055d1acd5086e69a442c14
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
